Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06378957 · ClinicalTrials.gov registry record · Phase 1
Behavioral Pharmacology of Orally Administered THC and D-limonene
A Phase 1 study of THC and Subjective Drug Effects, sponsored by Johns Hopkins University.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 65
- Enrollment target
- 1
- Study location
NCT06378957: Recruiting Phase 1 study of THC and Subjective Drug Effects, sponsored by Johns Hopkins University.
NCT06378957 is a Phase 1 study of THC and Subjective Drug Effects that is actively recruiting participants, run by Johns Hopkins University. The registered enrollment target is 65 participants, above the 50-participant average among 9 other THC trials with a reported enrollment target (30% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06378957, a Phase 1 study of THC and Subjective Drug Effects, is actively recruiting participants, sponsored by Johns Hopkins University.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 65 participants
- Enrollment target
- 1
- Study location
Study Summary
The current clinical trial will investigate the effects of orally administered d-limonene (limonene), delta-9-tetrahydrocannabinol (THC) and the combination in healthy adult volunteers.
Primary Outcome
Subjective drug effect will be measured on a 100 point visual analog scale (VAS) where 0 = no drug effect and 100 = strongest drug effect imaginable
Conditions Studied
Interventions
- DRUG Placebo
- DRUG D-Limonene
- DRUG Delta-9-THC
Study Locations (1)
Maryland
- Johns Hopkins Behavioral Pharmacology Research Unit - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2025-02-14 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 1 |
What NCT06378957 shows while recruiting
NCT06378957 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 65 participants, a relatively small participant target, above the 50-participant average among 9 other THC trials with a reported enrollment target (30% higher).
The record links to 3 conditions, with THC appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06378957 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT06378957 about?
NCT06378957 is a clinical study titled "Behavioral Pharmacology of Orally Administered THC and D-limonene". The current clinical trial will investigate the effects of orally administered d-limonene (limonene), delta-9-tetrahydrocannabinol (THC) and the combination in healthy adult volunteers.
What is the current status of trial NCT06378957?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 65 participants. The study started on 2025-02-14. Estimated completion is 2027-12-31.
What conditions does trial NCT06378957 study?
This clinical trial studies the following conditions: THC, Subjective Drug Effects, D-limonene.
What interventions are being tested in trial NCT06378957?
The interventions under investigation include: Placebo (DRUG), D-Limonene (DRUG), Delta-9-THC (DRUG).
Who is sponsoring clinical trial NCT06378957?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06378957 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for THC
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06378957's enrollment target sits among peer trials
65 4th of 9 higher than 6 of 9 other THC trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other THC trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
THC Memory & Reward Learning Pilot
ACTIVE NOT RECRUITING · Phase 1
-
Behavioral Pharmacology of THC and Alpha-pinene
COMPLETED · Phase 1
-
Pilot fMRI Studies of Aging-Related Effects of THC
RECRUITING · Phase 2
-
Effects of Cannabidiol and Tetrahydrocannabinol on Microbiome and Neuroinflammation in HIV
RECRUITING · Phase 2
-
Cannabis THC Potency, Metabolism, and Cognitive Impairment in Young Adults
RECRUITING · NA
-
Understanding the Clinical Pharmacology of Marijuana-Tobacco Co-administration
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03366116 · 65 participants · Phase 1
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors
- NCT03603730 · 65 participants · NA
Vagal Nerve Stimulation for Functional Dyspepsia and Gastroparesis
- NCT03796559 · 65 participants · NA
Magseed Enabled Long-Term Localization of Axillary Lymph Nodes
- NCT03993106 · 65 participants · Phase 2
A Study of sEphB4-HSA in Kaposi Sarcoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI